Plasma NfL is associated with the APOE ε4 allele, brain imaging measurements of neurodegeneration, and lower recall memory scores in cognitively unimpaired late-middle-aged and older adults.
Journal
Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643
Informations de publication
Date de publication:
10 04 2023
10 04 2023
Historique:
received:
26
08
2022
accepted:
28
03
2023
medline:
12
4
2023
entrez:
10
4
2023
pubmed:
11
4
2023
Statut:
epublish
Résumé
Plasma neurofilament light (NfL) is an indicator of neurodegeneration and/or neuroaxonal injury in persons with Alzheimer's disease (AD) and a wide range of other neurological disorders. Here, we characterized and compared plasma NfL concentrations in cognitively unimpaired (CU) late-middle-aged and older adults with two, one, or no copies of the APOE ε4 allele, the major genetic risk factor for AD. We then assessed plasma NfL associations with brain imaging measurements of AD-related neurodegeneration (hippocampal atrophy and a hypometabolic convergence index [HCI]), brain imaging measurements of amyloid-β plaque burden, tau tangle burden and white matter hyperintensity volume (WMHV), and delayed and total recall memory scores. Plasma NfL concentrations were measured in 543 CU 69 ± 9 year-old participants in the Arizona APOE Cohort Study, including 66 APOE ε4 homozygotes (HM), 165 heterozygotes (HT), and 312 non-carriers (NC). Robust regression models were used to characterize plasma NfL associations with APOE ε4 allelic dose before and after adjustment for age, sex, and education. They were also used to characterize plasma NfL associations with MRI-based hippocampal volume and WMHV measurements, an FDG PET-based HCI, mean cortical PiB PET measurements of amyloid-β plaque burden and meta-region-of-interest (meta-ROI) flortaucipir PET measurements of tau tangle burden, and Auditory Verbal Learning Test (AVLT) Delayed and Total Recall Memory scores. After the adjustments noted above, plasma NfL levels were significantly greater in APOE ε4 homozygotes and heterozygotes than non-carriers and significantly associated with smaller hippocampal volumes (r = - 0.43), greater tangle burden in the entorhinal cortex and inferior temporal lobes (r = 0.49, r = 0.52, respectively), and lower delayed (r = - 0.27), and total (r = - 0.27) recall memory scores (p < 0.001). NfL levels were not significantly associated with PET measurements of amyloid-β plaque or total tangle burden. Plasma NfL concentrations are associated with the APOE ε4 allele, brain imaging biomarkers of neurodegeneration, and less good recall memory in CU late-middle-aged and older adults, supporting its value as an indicator of neurodegeneration in the preclinical study of AD.
Sections du résumé
BACKGROUND
Plasma neurofilament light (NfL) is an indicator of neurodegeneration and/or neuroaxonal injury in persons with Alzheimer's disease (AD) and a wide range of other neurological disorders. Here, we characterized and compared plasma NfL concentrations in cognitively unimpaired (CU) late-middle-aged and older adults with two, one, or no copies of the APOE ε4 allele, the major genetic risk factor for AD. We then assessed plasma NfL associations with brain imaging measurements of AD-related neurodegeneration (hippocampal atrophy and a hypometabolic convergence index [HCI]), brain imaging measurements of amyloid-β plaque burden, tau tangle burden and white matter hyperintensity volume (WMHV), and delayed and total recall memory scores.
METHODS
Plasma NfL concentrations were measured in 543 CU 69 ± 9 year-old participants in the Arizona APOE Cohort Study, including 66 APOE ε4 homozygotes (HM), 165 heterozygotes (HT), and 312 non-carriers (NC). Robust regression models were used to characterize plasma NfL associations with APOE ε4 allelic dose before and after adjustment for age, sex, and education. They were also used to characterize plasma NfL associations with MRI-based hippocampal volume and WMHV measurements, an FDG PET-based HCI, mean cortical PiB PET measurements of amyloid-β plaque burden and meta-region-of-interest (meta-ROI) flortaucipir PET measurements of tau tangle burden, and Auditory Verbal Learning Test (AVLT) Delayed and Total Recall Memory scores.
RESULTS
After the adjustments noted above, plasma NfL levels were significantly greater in APOE ε4 homozygotes and heterozygotes than non-carriers and significantly associated with smaller hippocampal volumes (r = - 0.43), greater tangle burden in the entorhinal cortex and inferior temporal lobes (r = 0.49, r = 0.52, respectively), and lower delayed (r = - 0.27), and total (r = - 0.27) recall memory scores (p < 0.001). NfL levels were not significantly associated with PET measurements of amyloid-β plaque or total tangle burden.
CONCLUSIONS
Plasma NfL concentrations are associated with the APOE ε4 allele, brain imaging biomarkers of neurodegeneration, and less good recall memory in CU late-middle-aged and older adults, supporting its value as an indicator of neurodegeneration in the preclinical study of AD.
Identifiants
pubmed: 37038190
doi: 10.1186/s13195-023-01221-w
pii: 10.1186/s13195-023-01221-w
pmc: PMC10084600
doi:
Substances chimiques
Apolipoprotein E4
0
Amyloid beta-Peptides
0
tau Proteins
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
74Subventions
Organisme : NIA NIH HHS
ID : R01 AG069453
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG019610
Pays : United States
Organisme : European Research Council
ID : 681712
Pays : International
Organisme : NIA NIH HHS
ID : R01 AG041851
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG006786
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG072980
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG016574
Pays : United States
Organisme : NIA NIH HHS
ID : R37 AG011378
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG031581
Pays : United States
Informations de copyright
© 2023. The Author(s).
Références
Neuroimage. 2012 Feb 15;59(4):3774-83
pubmed: 22119648
JAMA Neurol. 2019 Jul 1;76(7):791-799
pubmed: 31009028
Neurobiol Dis. 2023 Jan;176:105937
pubmed: 36462720
Gerontologist. 1969 Autumn;9(3):179-86
pubmed: 5349366
J Neuropathol Exp Neurol. 2019 Jul 15;:
pubmed: 31305887
J Appl Stat. 2021 May 18;49(11):2870-2890
pubmed: 36299400
Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3334-9
pubmed: 11248079
Alzheimers Dement (Amst). 2019 Sep 27;11:679-689
pubmed: 31673598
Neurology. 1984 Jul;34(7):939-44
pubmed: 6610841
Brain. 2023 Feb 13;146(2):690-699
pubmed: 35383826
CNS Spectr. 2008 Jan;13(1):45-53
pubmed: 18204414
Alzheimers Dement (Amst). 2020 Sep 24;12(1):e12104
pubmed: 33005724
Nat Med. 2019 Feb;25(2):277-283
pubmed: 30664784
Alzheimers Dement. 2018 Apr;14(4):535-562
pubmed: 29653606
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
J Gerontol. 1982 May;37(3):323-9
pubmed: 7069156
Acta Neuropathol Commun. 2019 Jan 9;7(1):5
pubmed: 30626432
Alzheimers Dement. 2014 Jan;10(1):84-92
pubmed: 23541188
Alzheimers Res Ther. 2018 Nov 3;10(1):113
pubmed: 30390718
Alzheimers Dement. 2020 Mar;16(3):512-523
pubmed: 31787561
Proc Natl Acad Sci U S A. 2009 Apr 21;106(16):6820-5
pubmed: 19346482
N Engl J Med. 2009 Jul 16;361(3):255-63
pubmed: 19605830
Nat Rev Neurol. 2018 Nov;14(11):639-652
pubmed: 30297701
N Engl J Med. 1996 Mar 21;334(12):752-8
pubmed: 8592548
Neurobiol Aging. 2021 Jun;102:64-72
pubmed: 33765432
J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62
pubmed: 14399272
Alzheimers Dement. 2021 May;17(5):813-821
pubmed: 33527648
Neurology. 2011 Apr 19;76(16):1383-8
pubmed: 21502596
Lancet Neurol. 2020 Jun;19(6):513-521
pubmed: 32470423
Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8299-302
pubmed: 15932949
Neurology. 2006 Aug 8;67(3):446-52
pubmed: 16894106
Alzheimers Dement. 2021 May;17(5):801-812
pubmed: 33663022
Neurobiol Dis. 2020 Aug;142:104960
pubmed: 32522711
J Alzheimers Dis. 2008 Oct;15(2):303-25
pubmed: 18953116
Alzheimers Dement. 2017 Mar;13(3):205-216
pubmed: 27697430
Eur J Clin Invest. 2023 Mar;53(3):e13910
pubmed: 36401799
Neuroimage. 2011 May 1;56(1):52-60
pubmed: 21276856
Nat Rev Neurol. 2020 May;16(5):265-284
pubmed: 32322100
Alzheimers Dement (Amst). 2020 Sep 13;12(1):e12099
pubmed: 32995466
Neuroimage. 2012 Aug 15;62(2):774-81
pubmed: 22248573